[go: up one dir, main page]

FR2775189B1 - Compositions anti-tumorales a base d'antigenes hla-g ou d'anticorps anti-hla-g - Google Patents

Compositions anti-tumorales a base d'antigenes hla-g ou d'anticorps anti-hla-g

Info

Publication number
FR2775189B1
FR2775189B1 FR9809470A FR9809470A FR2775189B1 FR 2775189 B1 FR2775189 B1 FR 2775189B1 FR 9809470 A FR9809470 A FR 9809470A FR 9809470 A FR9809470 A FR 9809470A FR 2775189 B1 FR2775189 B1 FR 2775189B1
Authority
FR
France
Prior art keywords
hla
antigens
antibodies
compositions based
tumor compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9809470A
Other languages
English (en)
Other versions
FR2775189A1 (fr
Inventor
Edgardo Delfino Carosella
Jean Dausset
Philippe Moreau
Pascale Paul
Freiss Nathalie Rouas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9809470A priority Critical patent/FR2775189B1/fr
Application filed by Commissariat a lEnergie Atomique CEA filed Critical Commissariat a lEnergie Atomique CEA
Priority to DE69918413T priority patent/DE69918413T2/de
Priority to JP2000532142A priority patent/JP4470007B2/ja
Priority to PCT/FR1999/000386 priority patent/WO1999042128A1/fr
Priority to EP99904919A priority patent/EP1054688B1/fr
Priority to US09/622,583 priority patent/US6790638B1/en
Priority to CA002321222A priority patent/CA2321222A1/fr
Priority to ES99904919T priority patent/ES2224603T3/es
Publication of FR2775189A1 publication Critical patent/FR2775189A1/fr
Application granted granted Critical
Publication of FR2775189B1 publication Critical patent/FR2775189B1/fr
Priority to US10/788,374 priority patent/US20040209296A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FR9809470A 1998-02-20 1998-07-24 Compositions anti-tumorales a base d'antigenes hla-g ou d'anticorps anti-hla-g Expired - Fee Related FR2775189B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR9809470A FR2775189B1 (fr) 1998-07-24 1998-07-24 Compositions anti-tumorales a base d'antigenes hla-g ou d'anticorps anti-hla-g
JP2000532142A JP4470007B2 (ja) 1998-02-20 1999-02-19 Ｈｌａ−ｇを発現する、抗癌治療に感受性な腫瘍を選択する方法およびその使用
PCT/FR1999/000386 WO1999042128A1 (fr) 1998-02-20 1999-02-19 Methode de selection de tumeurs exprimant hla-g, sensibles a un traitement anticancereux et ses applications
EP99904919A EP1054688B1 (fr) 1998-02-20 1999-02-19 Methode de selection de tumeurs exprimant hla-g, sensibles a un traitement anticancereux et ses applications
DE69918413T DE69918413T2 (de) 1998-02-20 1999-02-19 Auswahlverfahren von hla-g exprimierenden tumoren, die durch antikrebsmittel behandelbar sind, und deren verwendungen
US09/622,583 US6790638B1 (en) 1998-02-20 1999-02-19 Method for selecting tumours expressing HLA-G, sensitive to anticancer treatment and uses
CA002321222A CA2321222A1 (fr) 1998-02-20 1999-02-19 Methode de selection de tumeurs exprimant hla-g, sensibles a un traitement anticancereux et ses applications
ES99904919T ES2224603T3 (es) 1998-02-20 1999-02-19 Procedimiento de seleccion de tumores que expresan hla-g sensibles a un tratamiento anticanceroso y sus aplicaciones.
US10/788,374 US20040209296A1 (en) 1998-02-20 2004-03-01 Method for selecting tumours expressing HLA-G which are sensitive to anticancer treatment, and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9809470A FR2775189B1 (fr) 1998-07-24 1998-07-24 Compositions anti-tumorales a base d'antigenes hla-g ou d'anticorps anti-hla-g

Publications (2)

Publication Number Publication Date
FR2775189A1 FR2775189A1 (fr) 1999-08-27
FR2775189B1 true FR2775189B1 (fr) 2001-06-08

Family

ID=9528977

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9809470A Expired - Fee Related FR2775189B1 (fr) 1998-02-20 1998-07-24 Compositions anti-tumorales a base d'antigenes hla-g ou d'anticorps anti-hla-g

Country Status (1)

Country Link
FR (1) FR2775189B1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021317111A1 (en) 2020-07-29 2023-03-30 Janssen Biotech, Inc. Proteins comprising HLA-G antigen binding domains and their uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05246889A (ja) * 1992-03-05 1993-09-24 Seitai Chiyousetsu Kenkyusho:Kk 制癌方法および制癌剤
FR2717498B1 (fr) * 1994-03-18 1996-05-03 Commissariat Energie Atomique Transcrits du gène de CMH de classe I HLA-G et leurs applications.
US6218363B1 (en) * 1996-08-28 2001-04-17 Thomas Jefferson University MHC peptides and methods of use

Also Published As

Publication number Publication date
FR2775189A1 (fr) 1999-08-27

Similar Documents

Publication Publication Date Title
FI972945A7 (fi) Antigeenien antamiseen soveltuvia koostumuksia
FI20115005L (fi) Melanooma-antigeeni
FI964235A0 (fi) Melanooma-antigeeni
DE69608823D1 (de) Seriendrucker
DE69403209D1 (de) Gesintertes selbstarmiertes siliciumnitrid
OA08477A (fr) Compositions d'anticorps monoclonaux humains à protection multiple.
NO993694D0 (no) Sylfonylurea- og adjuvansbaserte faste blandinger
DE69026492D1 (de) Siliciumnitridkörper
EP0888126A4 (fr) Vaccin a base d'un anticorps antiidiotype
EP0670494A3 (fr) Essai immunologique d'anticorps anti-tréponèmes.
FR2775189B1 (fr) Compositions anti-tumorales a base d'antigenes hla-g ou d'anticorps anti-hla-g
EP0834741A4 (fr) Dosage immunologique a l'or colloidal
EP0991321A4 (fr) Tolerance a des antigenes d'anticorps naturels
FR2759747B1 (fr) Clip d'agrafage
IT1292163B1 (it) Dispositivo immunocromatografico a fissazione dell'analita
DE59307850D1 (de) Si/SiGe BARITT-Diode
DE69503248D1 (de) Gesinterte reaktionsgebundene siliciumnitridbauteile
SE9802270D0 (sv) Novelautoantigen 3
FI954823A0 (fi) Tiivistetty säkki
MA26665A1 (fr) Combination d'anticorps
SK1637U (sk) Zahustená mliečna zmes
FI991120A0 (fi) Vesiliukoisten peptidien pitkäaikaisesti vapautuvat koostumukset
DE69217647D1 (de) Siliciumnitrid-sinterkörper
EP0919617A4 (fr) Anticorps monoclonal anti-mp52 humaine
KR960004964U (ko) 음용수용기 받침구

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20081031